Over-expression of Sox4 and β-catenin is associated with a less favorable prognosis of osteosarcoma

Abstract

The purpose of this study was to examine the association of the expression of Sox4 and β-catenin with the prognosis of osteosarcoma. A total of 108 cases of conventional osteosarcoma were involved in this study and 28 cases of osteochondroma served as controls. The expression of Sox4 and β-catenin was detected by using immunohistochemical staining and Western blotting. The results showed that Sox4 and β-catenin were over-expressed in 67 (62.03%) and 62 (57.41%) of 108 osteosarcoma cases, while in only 3 (10.71%) and 5 (17.86%) of 28 controls, respectively (P<0.05 for all). The expression of Sox4 and β-catenin was associated with the distant metastasis, pathological grade and Enneking stage of patients with osteosarcoma (P<0.05 for all). The mean overall survival time and the 5-year-survival rate in osteosarcoma patients with Sox4 and β-catenin over-expressed were significantly reduced as compared with those in Sox4 and β-catenin low-expression group (P<0.05 for all). Cox multifactor regression analysis revealed that the distant metastasis, Enneking stage, and the expression of Sox4 and β-catenin were independent risk factors of patients with osteosarcoma (P<0.05 for all). The findings indicated that overexpression of Sox4 and β-catenin is associated with a poor prognosis of osteosarcoma.

Keywords

osteosarcoma / osteochondroma / Sox4 / β-catenin / prognosis

References

[1] KongC, HansenMF. Biomarkers in osteosarcoma. Expert Opin Med Diagn, 2009, 3(1): 13-23 PMID: 20574545 PMCID: 2889491

[2] HattingerCM, PaselloM, FerrariS, et al. . Emerging drugs for high-grade osteosarcoma. Expert Opin Emerg Drugs, 2010, 15(4): 615-634 PMID: 20690888

[3] JaffeN, JaffeDM. Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol, 1996, 14(8): 2399-2400 PMID: 8708733

[4] GroupEESNW. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2012, 23: vii100-vii109

[5] OsborneTS, KhannaC. A review of the association between osteosarcoma metastasis and protein translation. J Comp Pathol, 2012, 146(2): 132-142 PMID: 22297074 PMCID: 3496179

[6] KamachiY, KondohH. Sox proteins: regulators of cell fate specification and differentiation. Development, 2013, 140(20): 4129-4144 PMID: 24086078

[7] ScharerCD, McCabeCD, Ali-SeyedM, et al. . Genome-wide promoter analysis of the SOX4 transcriptional network in prostate cancer cells. Cancer Res, 2009, 69(2): 709-717 PMID: 19147588 PMCID: 2629396

[8] KangM, LiY, LiuW, et al. . miR-129-2 suppresses proliferation and migration of esophageal carcinoma cells through downregulation of SOX4 expression. Int J Mol Med, 2013, 32(1): 51-58 PMID: 23677061

[9] SongGD, SunY, ShenH, et al. . SOX4 overexpression is a novel biomarker of malignant status and poor prognosis in breast cancer patients. Tumour Biol, 2015, 36(6): 4167-4173 PMID: 25592378

[10] WangD, HaoT, PanY, et al. . Increased expression of SOX4 is a biomarker for malignant status and poor prognosis in patients with non-small cell lung cancer. Mol Cell Biochem, 2015, 402(1): 75-82 PMID: 25567207

[11] LuoX, TangD, GaoT, et al. . MicroRNA-212 inhibits osteosarcoma cells proliferation and invasion by down-regulation of Sox4. Cell Physiol Biochem, 2014, 34(6): 2180-2188 PMID: 25562164

[12] CaiY, MohsenyAB, KarperienM, et al. . Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma. J Pathol, 2010, 220(1): 24-33 PMID: 19882675

[13] SinnerD, KordichJJ, SpenceJR, et al. . Sox17 and Sox4 differentially regulate beta-catenin/T-cell factor activity and proliferation of colon carcinoma cells. Mol Cell Biol, 2007, 27(22): 7802-7815 PMID: 17875931 PMCID: 2169141

[14] BhattaramP, Penzo-MendezA, KatoK, et al. . SOXC proteins amplify canonical WNT signaling to secure nonchondrocytic fates in skeletogenesis. J Cell Biol, 2014, 207(5): 657-671 PMID: 25452386 PMCID: 4259807

[15] ChaiDM, BaoZQ, HuJG, et al. . Vasculogenic mimicry and aberrant expression of HIF-lalpha/E-cad are associated with worse prognosis of esophageal squamous cell carcinoma. J Huazhong Univ Sci Technol [Med Sci], 2013, 33(3): 385-391

[16] GunBD, BahadirB, BektasS, et al. . Clinicopathological significance of fascin and CD44v6 expression in endometrioid carcinoma. Diagn Pathol, 2012, 7: 80 PMID: 22784357 PMCID: 3407727

[17] DuLL, ChaiDM, ZhouXW, et al. . AMPK activation ameliorates AD-like pathology and spatial memory impairment in a streptozotocin-induced Alzheimer’s disease model in rats. J Alzheimers Dis, 2015, 43(3): 775-84 PMID: 25114075

[18] HoserM, BaaderSL, BoslMR, et al. . Prolonged glial expression of Sox4 in the CNS leads to architectural cerebellar defects and ataxia. J Neurosci, 2007, 27(20): 5495-5505 PMID: 17507571

[19] DyP, Penzo-MendezA, WangH, et al. . The three SoxC proteins—Sox4, Sox11 and Sox12—exhibit overlapping expression patterns and molecular properties. Nucleic Acids Res, 2008, 36(9): 3101-3117 PMID: 18403418 PMCID: 2396431

[20] BusslingerM. Transcriptional control of early B cell development. Annu Rev Immunol, 2004, 22: 55-79 PMID: 15032574

[21] Van BeestM, van DooijesD, DeW, et al. . Sequence-specific high mobility group box factors recognize 10-12-base pair minor groove motifs. J Biol Chem, 2000, 275(35): 27266-27273 PMID: 10867006

[22] MuL, BertiL, MasserdottiG, et al. . SoxC transcription factors are required for neuronal differentiation in adult hippocampal neurogenesis. J Neurosci, 2012, 32(9): 3067-3080 PMID: 22378879 PMCID: 3356877

[23] AaboeM, Birkenkamp-DemtroderK, WiufC, et al. . SOX4 expression in bladder carcinoma: clinical aspects and in vitro functional characterization. Cancer Res, 2006, 66(7): 3434-3442 PMID: 16585165

[24] ZhangJ, LiangQ, LeiY, et al. . SOX4 induces epithelial-mesenchymal transition and contributes to breast cancer progression. Cancer Res, 2012, 72(17): 4597-4608 PMID: 22787120

[25] KuwaharaM, YamashitaM, ShinodaK, et al. . The transcription factor Sox4 is a downstream target of signaling by the cytokine TGF-beta and suppresses T(H)2 differentiation. Nat Immunol, 2012, 13(8): 778-786 PMID: 22751141 PMCID: 3477402

[26] JafarnejadSM, ArdekaniGS, GhaffariM, et al. . Pleiotropic function of SRY-related HMG box transcription factor 4 in regulation of tumorigenesis. Cell Mol Life Sci, 2013, 70(15): 2677-2696 PMID: 23080209

[27] HartmannC. A Wnt canon orchestrating osteoblastogenesis. Trends Cell Biol, 2006, 16(3): 151-158 PMID: 16466918

[28] NiehrsC. The complex world of WNT receptor signalling. Nat Rev Mol Cell Biol, 2012, 13(12): 767-779 PMID: 23151663

[29] Abdel-MagidAF. Wnt/beta-catenin signaling pathway inhibitors: A promising cancer therapy. ACS Med Chem Lett, 2014, 5(9): 956-957 PMID: 25264477 PMCID: 4173633

[30] ChenK, FallenS, AbaanHO, et al. . Wnt10b induces chemotaxis of osteosarcoma and correlates with reduced survival. Pediatr Blood Cancer, 2008, 51(3): 349-355 PMID: 18465804

[31] GuoY, ZiX, KoontzZ, et al. . Blocking Wnt/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition and suppresses met and metalloproteinases in osteosarcoma Saos-2 cells. J Orthop Res, 2007, 25(7): 964-971 PMID: 17318900

[32] ChengDD, ZhaoHG, YangYS, et al. . GSK3beta negatively regulates HIF1alpha mRNA stability via nucleolin in the MG63 osteosarcoma cell line. Biochem Biophys Res Commun, 2014, 443(2): 598-603 PMID: 24333432

[33] HoangBH, KuboT, HealeyJH, et al. . Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. Cancer Res, 2004, 64(8): 2734-2739 PMID: 15087387

[34] HaydonRC, DeyrupA, IshikawaA, et al. . Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma. Int J Cancer, 2002, 102(4): 338-342 PMID: 12402302 PMCID: 4122310

[35] XuS, YangZ, ZhangJ, et al. . Increased levels of beta-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2. DNA Cell Biol, 2015, 34(1): 69-77 PMID: 25343173 PMCID: 4281839

[36] WangH, WangH, MakkiMS, et al. . Overexpression of beta-catenin and cyclinD1 predicts a poor prognosis in ovarian serous carcinomas. Int J Clin Exp Pathol, 2014, 7(1): 264-271 PMID: 24427347 PMCID: 3885481

[37] LuN, LinT, WangL, et al. . Association of SOX4 regulated by tumor suppressor miR-30a with poor prognosis in low-grade chondrosarcoma. Tumour Biol, 2015, 36(5): 3843-3852 PMID: 25572678

[38] LiaoYL, SunYM, ChauGY, et al. . Identification of SOX4 target genes using phylogenetic footprinting-based prediction from expression microarrays suggests that overexpression of SOX4 potentiates metastasis in hepatocellular carcinoma. Oncogene, 2008, 27(42): 5578-5589 PMID: 18504433

[39] LiuP, RamachandranS A, SeyedM, et al. . Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res, 2006, 66(8): 4011-4019 PMID: 16618720

[40] LiuY, LiY, LiuJ, et al. . MicroRNA-132 inhibits cell growth and metastasis in osteosarcoma cell lines possibly by targeting Sox4. Int J Oncol, 2015, 47(5): 1672-1684 PMID: 26352673 PMCID: 4599193